Assembling Amperometric Biosensors for Clinical Diagnostics by Belluzo, María Soledad et al.
Sensors 2008, 8, 1366-1399 
sensors 
ISSN 1424-8220 
© 2008 by MDPI 
www.mdpi.org/sensors 
Review 
Assembling Amperometric Biosensors for Clinical Diagnostics  
María Soledad Belluzo, María Élida Ribone and Claudia Marina Lagier * 
 
Analytical Chemistry Department, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad 
Nacional de Rosario, Suipacha 531, Rosario –2000- Argentina. 
 
* Author to whom correspondence should be addressed. E-mail: clagier@fbioyf.unr.edu.ar 
Received: 1 February 2008 / Accepted: 14 February 2008 / Published: 27 February 2008 
 
Abstract: Clinical diagnosis and disease prevention routinely require the assessment of 
species determined by chemical analysis. Biosensor technology offers several benefits over 
conventional diagnostic analysis. They include simplicity of use, specificity for the target 
analyte, speed to arise to a result, capability for continuous monitoring and multiplexing, 
together with the potentiality of coupling to low-cost, portable instrumentation. This work 
focuses on the basic lines of decisions when designing electron-transfer-based biosensors 
for clinical analysis, with emphasis on the strategies currently used to improve the device 
performance, the present status of amperometric electrodes for biomedicine, and the trends 
and challenges envisaged for the near future. 
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1. Introduction 
Current methodologies to determine the species that define or identify one particular clinical 
condition present several drawbacks, even when leading to reliable results. Requirements of previous 
separative steps, the need to count with highly trained personnel to perform the analysis, its frequent 
high cost, the circumscription to state-of-the-art laboratories are, among others, the main reasons that 
have prompt the search for new analytical technology to achieve advantageous clinical diagnostic 
methods [1]. Biosensors emerge as upbeat technology to face this challenge. 
Biosensors have been defined as compact analytical devices that bring together the use of a 
biological, a biologically-derived or a biomimic element to recognize the analyte. They are closely 
associated with, or integrated to, a signal conversion unit, the so-called physicochemical transducer, 
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which eventually leads to a read-out. The use of biological materials as recognizing elements gives 
biosensors a remarkable ability to specifically react with the analyte of interest, distinguishing it from 
structurally similar compounds.  
Taking into account the biomolecule that recognizes the target analyte, biosensors can be named as 
(i) affinity sensors, when the bioreceptor uses non-covalent interactions like antibody-antigen reactions 
or DNA strand hybridisation, and (ii) catalytic or enzyme sensors, when the analyte is the enzyme 
substrate, or it can be detected by measuring the signal produced by one substrate or product of the 
enzymatic reaction involving the analyte. Biosensors are also classified according to the parameter that 
is measured by the physicochemical transducer of the biological event. Thus, classically biosensors are 
grouped into optical, electrochemical, acoustic and thermal ones. Considering that electrochemical 
reactions directly generate an electronic signal, biosensors based on this approach greatly simplifies 
signal transduction, avoiding expensive equipment requirement. 
Among electrochemical biosensors, the oldest ones, which have led to the higher number of ready-
to-use devices, are based on the monitoring of electron-transfer processes, thus belonging to the 
amperometric category. This review will centre on this group. The signal of these biosensors is 
generated by the electron exchange between the biological system in the bioreceptor layer and one 
electrode. Generally speaking, when using amperometric biosensors, the analyte undergoes, or is 
involved, in a redox reaction that can be followed by measuring the current in an electrochemical cell. 
The analyte, or the species involved with it via a (bio)chemical reaction, changes its oxidation state at 
one electrode. The electron flux is then monitored and is proportional to the amount of the species 
electrochemically transformed at the electrode. Figure 1 depicts the working principles of an 
amperometric biosensor. 
 
Figure 1. Scheme depicting the functional principles of an amperometric biosensor. 
 
The typical electrochemical technique performed when working with electron-transfer-based 
biosensors is chronoamperometry, in which the current is measured as a function of time, when the 
electrode is driven at an appropriate constant potential. Figure 2A shows a standard curve obtained 
when using an amperometric bioelectrode, in which the current varies upon the addition of a particular 
compound (e.g. a redox-enzyme substrate) to render a particular product that is electro-transformed at 
the electrode. The current change registered is proportional to the amount of electro-oxidized/reduced 
species, which in turn may be directly or inversely proportional to the analyte concentration, 
depending on the assay format.  
signal = current
sample applied potential
e-
= analyte = bioreceptor
transductor
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Other electrochemical techniques, based on the electrochemical oxidation/reduction of species 
directly or indirectly involved in the recognizing biological reaction have been used when dealing with 
electron-transfer based biosensors. For example, it is possible to follow the amount of a species that is 
electro-transformed at one electrode by monitoring the time taken to perform such a reaction, when 
working at constant current, and varying the electrode potential. Fig. 2B depicts a typical curve 
obtained when carrying out one of these experiments, named potentiometric stripping analysis. The 
peak area is proportional to the time necessary to electro-transform a species attached to the electrode, 
which, for example, may be directly proportional to the analyte concentration.  
 
Figure 2. Typical plots of the signals obtained when using electrochemical biosensors 
based on the amount of electro-transformed species at the electrode by means of (A) 
chronoamperometry, and (B) potentiometric stripping analysis.  
 
Several other electrochemical techniques are also employed when using electron-transfer-based 
biosensors, such as stripping voltamperometry, differential pulse voltamperometry, coulometry, etc. 
These methodologies essentially measure parameters related to the amount of electro-transformed 
material on the electrode as current flows in the cell.  
Clark and Lyons presented the precursor of today’s biosensors in the early sixties [2], though it was 
named “the enzyme electrode” rather than a glucose amperometric bioelectrode (Figure 3). The 
analyte, glucose, diffuses through a dialysis membrane to reach the trapped enzyme, glucose oxidase, 
which is placed very close to the surface of a platinum electrode. In the presence of the enzyme and 
oxygen, the analyte produces glucuronic acid and hydrogen peroxide. Monitoring the decrease in 
oxygen concentration allows to determine the glucose concentration of the medium bathing the outside 
face of the dialysis membrane. In this case, oxygen is reduced at the metal electrode polarized with a 
constant potential, and the current flowing in the cell is proportional to the oxygen concentration in the 
solution. Soon after Clark’s proposal, Updike et al. introduced modifications to this first approach to 
avoid oxygen concentration dependence. They monitored the current flowing in the cell when one of 
the products of the enzymatic reaction, hydrogen peroxide, was oxidized on an electrode at a 
convenient potential [3].  
Today, Clark’s brilliant, pioneering development has evolved, reaching the markets as “blood-
glucose, self-testing biosensors”. It is routinely used for screening and treating diabetes -an illness 
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whose prevalence is ca. 4% of the population in industrialized countries- the equipment being 
worldwide sold by leader sensor companies [4]. 
 
Figure 3. Illustration of Clark’s enzyme electrode displaying the reactions occurring at 
the inner solution containing the enzyme and at the electrode surface.2. Selectivity-
Specificity 
 
2.  Selectivity-Specificity 
2.1. Choosing the bioreceptor system 
The bioreceptor layer is responsible for the selectivity/specificity of the device and, in principle, 
any biological or biologically derived element can be used. Figure 4 summarizes the different 
bioreceptors we can use to achieve the desired selectivity, according to the nature of the analyte. 
It should be noticed that this is the foremost feature of biosensors, since provides the devices the 
capacity of working without previous treatments of the sample, thus conferring speed to the analysis. 
The first task when designing a biosensor is to select a suitable bioreceptor system so that the 
recognition sites interact specifically with the target analyte. This choice depends on the analyte 
properties and structure, and on the presence of similar interfering substances potentially present in the 
sample. In clinical-chemical analysis, we deal with biological samples, which display a complex 
matrix likely carrying interferences. 
 
 
 
 
glucose + O2 glucuronic acid + H2O2
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Figure 4. Bioreceptors eligible for attachment to the electrode surface. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.1. Enzymes 
The extraordinary specificity displayed by enzymes for their natural substrates makes them the first 
candidates to be incorporated as the biorecognition element. In principle, we can use redox enzymes 
that react with the analyte producing products that can be monitored by amperometry via their 
oxidation/reduction on an electrode, as it was illustrated above with Clark’s glucose biosensor. It is 
worth mentioning here that, when designing enzyme-based biosensors, an important issue is regaining 
the original oxidation state of the redox active site, so as to keep the enzyme active to react further 
with its substrate. Generally speaking, it is not feasible to oxidise/reduce the active site of one enzyme 
by setting directly the electrode potential at any particular value (an exception will be discussed later 
regarding oriented attachment of bioactive materials in point 3.1). Most of the enzymes used in 
biosensor technology have their redox centre inside a pocket or at the core of the protein, so that the 
active site is electrically insulated. This difficulty is commonly tackled by using redox charge 
mediators, which transport the charge between the enzyme active site and the electrode surface. This 
subject will be discussed later in section 2.2. 
Though it would be desirable to electrochemically detect changes in the enzyme substrate (the 
analyte) or in one reaction product, most of the analytes of clinical interest are not natural substrates of 
a redox enzyme. A variety of strategies have been developed to work this problem out, depending on 
the analyte chemical properties. They are based upon the fact that it is feasible to transform a non-
redox reaction into a redox one, which involves an enzyme that changes the oxidation number of the 
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species that can be monitored by amperometry. These enzymes are sometimes used as label or reporter 
of the biological recognition event. Consequently, it has been proposed the use of coupled enzymatic 
reactions following the one where the analyte participates, to finally produce a species detectable by 
amperometry. The design below has been proposed by Tsuchida et al. to detect creatine, an important 
product of protein catabolism, and creatinine, one indicator of kidney function [5]. The coupled 
reactions are shown in equations 1 to 3. They ultimately produce hydrogen peroxide, the species that is 
electrochemically transformed at the electrode to generate an amperometric signal. 
 
Other biosensors to determine analytes of clinic relevance have been developed, using redox 
enzymes that allow for the detection of the oxidation or reduction of one product directly or indirectly 
involved in the enzymatic reaction. They include amperometric biosensors to determine urea [6], 
lactate [7-9] and pyruvate [10], among others. 
2.1.2. Antibodies, antigens & aptamers 
When a foreign compound, called antigen (Agn), enters one individual’s body, its immunological 
system generally produces proteins, antibodies (Abs), which bind to such Agn with remarkable 
specificity. Nowadays, Abs can be either produced by inoculation of the Agn to an immuno-competent 
individual, or by genetic engineering of bacterial or animal cells [11]. Moreover, currently, it is 
possible to produce Abs against almost any molecule (analyte), even those unable to stimulate 
naturally the immune system [12].  
Biosensor technology has taken advantage of the high specificity of the Agn-Ab reaction and, since 
decades, a myriad of research work aimed to clinical-chemistry analysis was carried out [13]. Thus, 
when the clinical analyte of interest is an Agn, or it can be chemically modified to behave as an Agn, it 
is possible to use the complementary Abs as capturing molecules in the bioreceptor system. Abs 
usually interact exclusively with their complementary Agns, thus conferring a remarkable specificity 
to the device. In this case, the biosensor will be called immunosensor, named after the usage of Abs as 
bioreceptors.  
The use of one enzyme-labelled antigen, added together with the sample carrying the analyte, 
allows to perform a competitive assay, in a similar way to competitive, enzyme linked immunosorbent 
assays (ELISA). Figure 5A depicts the competitive immunosensor format, where the target analyte 
competes with the labelled antigen for the biorecognition sites of the antibody attached to the 
creatinine + H2O creatine (1)
glycine + formaldehyde + H2O2 (3)sarcosine + H2O + O2
creatine + H2O sarcosine + urea (2)
electroactive species
creatinine
amidinohydrolase
sarcosine oxidase
creatinine
amidohydrolase
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electrode. After rinsing the system, the addition of the redox-enzyme-label substrate generates the 
product, which is transformed at the electrode, or reacts with one electroactive enzyme co-substrate 
further added, leading to a detectable current. In this competitive assay, the signal diminishes as the 
analyte concentration increases. 
 
Figure 5. Scheme depicting different immunoassay formats using amperometric 
detection. (A) Biosensor to detect an antigen using a competitive immunoassay format, 
with a redox-enzyme-labelled antigen and the natural substrate of the enzyme, Ez. (B) 
Biosensor to detect a specific antibody using an indirect immunoassay format. 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnostic electron-transfer-based immunosensors have been reported to detect cancer markers, 
such as prostate specific antigen [14,15] and carcinoembryonic antigen [16], a pregnancy-indicator 
hormone, human chorionic gonadotrophine (hCG) [17], the hormone indicative of ovary function, 
progesterone [18], cholesterol [19], creatinine [20], and auto-antibodies of Type I diabetes [21], among 
others. The reader is referred to wide-ranging immunosensor reviews such as those listed in references 
[13,22,23]. 
When the analyte is an Ab, which is usually the case when diagnosing an infection, another 
immunological assay scheme can be performed, similar to that used to detect Agns. In this case, the 
bioreceptor is the Agn, which captures the specific Ab from the sample. A subsequently added redox, 
enzyme-labelled secondary Ab towards a particular region of the analyte (e.g. the Fc region of human 
immunoglobulin G, IgG, see below) will be captured on the surface of the modified electrode. The 
occurrence of a current once the substrate of the enzyme label is added evidences the presence of the 
analyte in the sample. In this case, one expects the signal to increase with the analyte concentration. 
Figure 5B illustrates the working principle of an indirect immunoassay format with amperometric 
detection. Biosensors using this format have been proposed by our group [24], and by Ferreira et al 
[25], to detect Chagas’ disease, the most serious parasitosis in South America. Other clinically relevant 
infections, such as those caused by Schistosoma japonicum [26,27] and hantavirus [28], have been 
detected with this strategy. 
Despite the outstanding specificity of the Agn-Ab reaction, sometimes, cross-reactions may occur. 
False-positive results are generally associated with the occurrence of non-specific Abs, which are often 
developed by individuals suffering from other diseases. For instance, when a patient is infected with a 
A
capturing Ab
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target analyte
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Electrode
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microorganism phylogenetically related with the one whose infection is to be determined, this 
individual may have produced Abs against orthologous proteins of both infective agents. Therefore, 
the use of natural proteins of the microorganism as capturing Agn may lead to incorrect results. In 
these cases, synthetic recombinant proteins can assist to work the problem out. Recombinant proteins 
are generally synthesized from DNA sequences engineered to encode peptide fragments where the 
specific regions responsible of cross-reactivity have been excised [29,30]. The use of recombinant 
DNA machinery to obtain specific, tailor-made proteins, together with biosensor technology, emerges 
as an auspicious means to achieve ready-to-use devices. They allow not only to obtain the analyte-
exclusive bioreceptor, but also to simplify their attachment to the electrode surface (see below, item 
3.2.). Our group has synthesized such proteins for chagasic infection diagnosis. Results obtained with 
amperometric biosensors assembled with the new synthetic proteins have been presented in a 
preliminary work [31]. The recombinant proteins produced allowed not only to obtain a unique 
analyte-capturing bioreceptor, but also to attach it to the electrode in an oriented manner. 
Recently, aptamers have also been used as analyte-capturing species. Aptamers are linear 
nucleotide sequences, usually of 15- to 40-nucleotide length, undergoing many intramolecular 
interactions, which wrinkle the oligonucleotide chain. Therefore, aptamers present a three-dimensional 
shape that confers the molecules the aptitude to interact either strongly or weakly with partner 
molecules, depending on their structure. The enormous diversity of aptamer conformational structure, 
which varies with the nucleotide sequence, allows them to be selected according to the strength of 
interaction with their partner molecule [32,33]. Thus, aptamers can be chosen so as to tightly and 
selectively bind to target molecules, including among them virtually any kind of analyte, e.g. proteins, 
lipids, carbohydrates, DNA, etc. [33,34]. Moreover, aptamers are easily synthesised and isolated. They 
are more stable than, for example, antibodies, allowing to build up robust biosensors that, at variable 
settings, do not lose their remarkable specificity [35,36]. These are the reasons why, in the lately years, 
scientists have preferred the use of aptamers as recognizing element when developing biosensors 
[33,37-43]. Numerous clinically related aptamer-based biosensors have been designed, as for example, 
one to detect 17β-estradiol, a hormone indicative of ovary function [44]. Likewise, electron-transferred 
based aptasensors to determine small molecules like cocaine in biological fluids have been also 
developed [45], as well as others to determine thrombin [46-48]; thrombin is the main executioner of 
the coagulation cascade, and its determination in blood is useful to assess the haemostatic status of 
patients for the diagnosis of coagulation and thrombotic disorders [49]. Another related aptasensor is 
the one used to determine simultaneously lysozyme and thrombin [50]; serum lysozyme has been 
proposed to be a marker of chronic inflammatory diseases, such as sarcoidosis, tuberculosis and liver 
and bowel inflammatory diseases, as well as of leukemia [51]. Extensive and detailed aptamer-based 
sensor technology is reviewed in references [33,34,42,52]. 
2.1.3. Nucleic acids 
Clinical-chemistry analysis often involves the detection of specific nucleotide sequences related to 
either a particular microorganism, which may be the causal agent of an infection, or DNA mutations 
that originate genetic diseases, or that are connected with high probability to develop certain type of  
diseases. Nucleic acid hybridisation is a thermodynamically favoured process, triggered by highly 
specific base-pairing interactions, where each nucleotide base strongly binds to its complementary 
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base through several hydrogen bonds, efficiently sticking the bases together. Accordingly, DNA/RNA 
strands are excellent applicants to be used as recognizing elements to build up bioreceptor layers. 
In the minimal configuration of amperometric DNA- or RNA-based biosensors, a single-stranded 
(ss-), nucleic acid sequence is anchored to an electrode to capture the analyte, in this case, its 
complementary DNA or RNA strand. Once the binding partners have met, the event is detected using 
different approaches, mostly by using an electrochemical reporter of the hybridisation [53-56]. Since 
the early sixties, Palecek and co-workers have been studying nucleic acids electrochemically [57-59], 
and have proposed a number of strategies to detect hybridisation [60-62]. A vast literature has been 
published on DNA hybridisation detection, some of them included in references [63-68]. Clinical 
applications using DNA-amperometric-based biosensors include devices potentially useful to 
determine indicators of pathogenic bacteria [69], virus DNA sequence such as that of SARS virus [70], 
indicators of chronic myelogenous leukemia [71], and acute promyelocytic leukemia [72]. We refer 
readers to references [73-75], since they are comprehensive reviews dealing with DNA-based 
biosensors.  
The simplest strategy to detect nucleic acid hybridisation relies on monitoring the direct 
oxidation/reduction of nucleotide bases. For example, the purine base guanine (G), can be oxidised at a 
particular potential, firstly rendering 7,8-dihydro-8-oxoG (commonly referred to as 8-oxoG), which 
suffers further oxidation reactions [76-78] (Figure 6A). In principle, the number of G residues present 
in the ss- nucleic acid probe will lead to a directly proportional reduction or oxidation signal. The most 
important drawback that presents this simple method to determine hybridisation is the high 
background current in the absence of the hybridisation event [75]. It should be considered that the G 
electrochemical signal diminishes upon base pairing; this has been ascribed to the molecule rigidity 
gained after hybridisation [79, and references therein], or to steric hindrance that prevents accessibility 
of the oxidation sites [80]. To overcome this inconvenience, the replace of G base by inosine, an 
hypoxantine-derivative nucleoside, proved to be useful [56,64], since its preferential base partner is the 
same as for G [81]. Therefore, there is a signal increase after pairing of DNA complementary strands, 
making this a suitable platform to detect the event. 
The use of cationic metal complexes that can associate to double-stranded (ds-) DNA stronger than 
to ss-DNA has been also proposed [53,54]. In this case, small complexes can intercalate between DNA 
grooves possessing a much higher affinity for the DNA hybridised compared to ss-DNA. The central 
metal ion can be electrochemically transformed when is close to the electrode surface, and therefore 
the signal increases as long as hybridisation takes place. A widely used DNA-intercalating metallic 
complex is Co(2,2'-bipyridy1)33+. This compound was used to detect the three-base deletion of ∆F508 
DNA sequence, an indicator useful to diagnose cystic fibrosis [54], and the presence of pathogenic 
Escherischia coli bacteria [53]. Another similar compound, Co(1,10-phenanthroline)33+, was also used 
to detect DNA sequence of Mycobacterium tuberculosis [82], Cryptosporidium parvum [83], hepatitis 
B virus [84], and the human immunodeficiency virus [82,85]. A variety of other intercalating 
compounds, such as methylen blue [86], daunomycin and aromatic amines [87], have been used to 
evidence DNA hybridisation. The two latter ones have been applied to detect the gene encoding for 
apolipoprotein E, a protein involved in familial dysbetalipoproteinemia [87]. Still another strategy 
taking advantage of labelled-complementary base sequences has proved to be effective to monitor 
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DNA hybridisation. Labels include electroactive molecules such as ferrocene derivatives [88] (Figure 
6B) or enzymes (Figure 6C) [89-91], as well as other redox-derivative compounds [92-95]. 
 
Figure 6. DNA-based biosensor arrangements. (A) Direct detection of DNA by electro-
oxidation of guanine using an electrode poised at a convenient potential. (B) 
Electrochemical detection of DNA hybridisation using an electrochemical mediator for 
the oxidation of guanine species, which bounds to the nucleic acid probe, and is 
afterwards electro-transformed. The signal reduces as the analyte concentration increases. 
(C) Electrochemical detection of DNA hybridisation using an oligonucleotide modified 
with a redox enzyme (Ez). The signal increases upon adding the enzyme substrate, once 
hybridisation took place. 
 
 
A variety of arrays have been reported to rise above the limitations and disadvantages occurring 
when using DNA-based biosensors, and some of them will be detailed in the following item. For a 
deeper insight on the subject, we refer the readers to exhaustive reviews, as those referenced next 
[75,96-98]. 
2.2. Avoiding interfering reactions 
Though there are many enzymes whose products can be monitored by amperometry, sometimes 
complications crop up using the simple model described in point 2.1.1, since other compounds present 
in the sample matrix may also be transformed on the electrode set at the chosen potential. The same 
holds true when directly detecting nucleic acid hybridisation via oxidation of G. Certainly, together 
with the species indicator of the biochemical event taking place at the biorecognition layer, 
interferences may also be electrochemically oxidised/reduced. For example, when using an 
amperometric glucose biosensor, which oxidises the hydrogen peroxide produced by the enzymatic 
reaction shown in Fig. 3, other endogenous substances, e.g. uric and ascorbic acid, gluthatione, 
cysteine, or exogenous compounds such as manitol, acetaminophene, thiocyanate etc., are also 
oxidised at the electrode potential [99-103]. In these cases, different strategies have contributed to 
solving the problem, namely: (i) preventing the interfering compound from occurring in a significant 
amount nearby the electrode and (ii) working at potentials at which oxidation/reduction of 
interferences is negligible. 
BA
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The simplest proposal to diminish occurrence of non-desired reactions at the electrode is simply by 
diluting the sample so that the interferences potentially present in the sample are not readily detected. 
However, this approach is only useful when dealing with highly sensitive devices, such as the one 
reported to detect uric acid using uricase [104].  
Another straightforward method to prevent interferences from reaching the electrode is by using a 
selectively-permeable membrane, which can operate based on either charge or size properties. One 
example of the charge rejection approach has been proposed by Zhang et al. [105]. They designed a 
blood glucose biosensor that uses a Nafion™ membrane to exclude interfering anions. Examples of 
interference-excluding membranes based upon size used for glucose amperometric biosensors include 
the dialysis type ones [100,106], polymers, such as overoxidized polypyrrol [107], 
polydimethylsiloxane [108], poly(1,2-diaminobenzene) [109], poly(1,3-diaminobenzene/resorcinol) 
[110,111], poly(o-phenylenediamine) [112] and cellulose acetate [113,114]. In all these cases, 
polymers allow for permeation of molecules having similar molecular weigh to the analyte, 
interferences of size larger than the analyte being excluded.  
Still another way to remove non-desirable species previously to the detection step is by capturing 
the analyte, and changing the medium where the electrochemical reaction will take place 
[59,60,62,115,116]. For example, Adam et al. have determined the presence of heavy metals in 
biological fluids with a biosensor which uses metallothionein, a cystein-rich protein that covalently 
binds heavy metals via its multiple sulfhydril residues [116,117]. The procedure consists of capturing 
the heavy metal ions by their interaction with the metallothionein protein, previously adsorbed on a 
hanging mercury drop electrode. After washing the electrode, a differential pulse voltammetry is 
performed in a convenient supporting electrolyte to register the corresponding signal [116,118]. 
Magnetic-bead-based biosensors relay on the same principle based on detection of the analyte 
subsequent to the separative step [119]. In brief, after pairing the target analyte with the biorecognizing 
element mounted on the beads, the coupled system is magnetically removed from the original sample 
matrix and transferred to an appropriate interference-free medium for further detection. A number of 
biosensors have been proposed to detect analytes of clinical interest using this strategy, the device 
proposed to detect BRCA1 breast cancer gene being one relevant example [120].  
The second tactic to avoid interfering reactions consists of working with systems that use electrode 
potentials at which interferences are not efficiently oxidized/reduced, which can be achieved by using 
electrochemical mediators [121-125]. Electrochemical mediators commonly used are chemicals 
displaying a higher kinetic constant for the electron transfer process at the electrode than that of the 
product selected to monitor the enzymatic reaction. Thus, the electro-transformation of the mediator 
(med) is favoured, as compared with that of the product of the enzymatic reaction. These compounds 
usually act as enzyme (Ez) co-substrates mediating the charge transport between the biological 
recognition element and the electrode, therefore rendering a catalytic cycle, as described in Fig. 7. 
It is worth pointing out that when such a catalytic cycle occurs, there is a substantial improvement 
of the methodology sensitivity due to the recycling of the electrochemically active species, which can 
be repetitively transformed. A variety of electrochemical mediators, either soluble or directly attached 
on the electrode, have been used. Most of them deal with the enzyme-electrically-wiring obstacle. 
Simultaneously, they prevent from electrochemical oxidation/reduction of interferences and, 
sometimes, they still improve sensitivity.  
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Figure 7. Catalytic cycle taking place when using an enzymatic amperometric 
bioelectrode and an electrochemical mediator that regenerates the original oxidation state 
of the enzyme redox site.  
 
Recently, Alves et al. have described a very interesting mediator for a glucose biosensor [126]. In 
this case, iron complexes derived from tetra-2-pyridyl-1,4-pyrazine have been mixed with 
hexacyanoferrate species to render a supramolecular structure that contains Fe(II) and Fe(III) species, 
inside a highly π-character network. This polymer exhibits an excellent conductivity together with 
catalytic activity for H2O2 electro-reduction, which is displayed by this Prussian Blue-analogue. 
Therefore, the polymer enables its coupling to a glucose-oxidase enzyme as a redox charge transfer 
mediator, working at a relatively low potential [126]. Reasonable good performances were also 
reported for mediators attached on bioelectrodes surface for glucose determination, which include 
tetracyanoquinodimethane, tetrathiafulvalene, dimethyl ferrocene [127,128], other ferrocene 
derivatives [129,130], complexes containing Os-bispyridine or derivatives [131-139], methyl viologen 
or derivatives [133,134], toluidine blue O [135], poly(allylamine)ferrocene [140,141], Os-
poly(allylamine) derivatives [142] and poly(aniline) derivatives [143], among others. Moreover, the 
ExacTECH™ biosensor from Abbott-Medisense takes advantage of the strategy, using in this case one 
ferrocene derivative as mediator to monitor glucose blood level [144]. Proposals of clinically-useful 
biosensors using soluble mediators to detect infection-marker antibodies [24,25], acetylcholine [145], 
biological oxygen demand [146], as well as other electrode-attached mediators to determine simple 
molecule analytes, such as glutathione [132], L-alanine and pyruvate [10], lactate [147], and 
cholesterol [129] accurately have been also reported. Chaubey et al. have published an extensive study 
on mediators for biosensor applications [148]. 
Likewise, clever improvements to avoid interference reactions and background currents have been 
proposed when detecting DNA hybridisation. Some approaches follow the same strategies as for 
enzymatic biosensors, i.e. physical separation of the analyte from interferences, decrease of working 
potentials, or both alternatives at the same time. In one of the proposed separative strategies, the DNA-
capturing probe is attached to magnetic beads and, once hybridisation is accomplished, the particles 
are magnetically removed from the medium. The analyte determination proceeds by electron-transfer-
based electrochemical techniques [60,120]. 
Once more, considering that the potentials at which the nucleotide bases are electro-transformed 
are quite extreme, severe interferences from oxidation/reduction of other species present in the sample 
make necessary additional steps to accurately detect hybridisation [56,59,79,149-151]. That has 
prompted the development of alternative approaches, as for example, detection of DNA hybridisation 
by electrocatalytic oxidation of ribose and primary amine residues of nucleotide bases, using copper 
surfaces [80]. In this approach ss-DNA signal was lower than that generated by ds-DNA, and allowed 
med Ox
med Red e-Ez ox
Ez red
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to detect nucleic acids in concentration at the picomolar level [80]. Another option to detect 
hybridisation is to oxidise G via a charge transfer mediator, for example the metallic complex Ru(2,2’-
bipyridyl)3+, which is easily electro-oxidised at a relatively low potential [152]. This strategy prevents 
from working at extreme potentials and it has proved success to detect, for example, a sequence of 
BRCA1 breast cancer gene [153]. 
Strategies used in biosensor technology to prevent interference reactions from species 
accompanying the analyte are detailed in reviews [63,74,75,96].  
2.3. Preserving the bioreceptor layer 
Bioreceptors must maintain appropriate biorecognition activity to be used in a biosensing device. 
Therefore, their structural/conformational integrity must be conserved so as to display a reasonable 
lifespan. It is obvious that, depending on the complexity of the biorecognition element, the 
requirements to maintain its integrity will change. In principle, any biological molecule or biomimic 
assembly capable of recognizing the analyte can be used as a bioreceptor. Table 1 summarizes the 
main needs to be taken into account according to the biorecognition element used in the bioreceptor 
layer. 
Table 1. Most important requirements to preserve the bioreceptor functionality 
Biorecognition layer (complexity order 
increases to the bottom) 
Main requests for functional integrity (the 
needs usually add up to the bottom) 
Single molecule 
Aptamer / ion carrier 
(ionophore) 
Appropriate withholding 
Antibody / DNA pH and saline stability 
Enzyme / high molecular 
weigh protein 
Absence of certain poisoning products 
(e.g. heavy metals) 
Membrane receptor Mechanic protection 
Organelle (chloroplast, mitochondrion, etc) Appropriate osmotic pressure, oxygen 
Cell 
Nutrients 
Tissue 
Organ Undamaged tissue 
 
From Clark’s first biosensor design, in which a dialysis membrane kept the bioreceptor, glucose 
oxidase, in a solution which preserved its integrity, changes were brought up attempting to improve the 
stability of the immobilized biorecognition element, and hence the lifetime of the biosensor. 
Numerous biosensors in which the recognizing elements are entrapped in passive matrices such as 
inert polymers, or where the analyte-capturing molecule is cross-linked with other spectator proteins, 
have been described [154,155]. In this line, it has been reported the development of diagnostic 
biosensors retaining the bioactive molecules via crosslinking with carbodiimide or glutaraldehyde to 
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detect, for example, prostate specific antigen [14], Schistosoma japonicum antibody [27], specific 
chagasic antibodies [25], transferrin [156], and creatinine [157], among others.  
Various different bioreceptor-capturing, entrapping polymers used to develop clinically suitable 
biosensors have been described. Among them, conducting polymers have demonstrated several 
advantages, such as (i) to give a support to the biologically-active molecule by chemical interactions, 
either electrostatic, covalent or non-specific interactions, (ii) to allow charge propagation and to “wire” 
the label (e.g. one redox-enzyme) to the electrode, (iii) to admit the incorporation of redox mediators, 
and (iv) to enhance mechanical resistance, turning devices more robust. Among these polymers, the 
pyrrol-based ones have been thoroughly characterised [158-161]. They display excellent properties to 
be used for biosensor development, since they render appropriate stability and good conductivity 
[162]. Polypyrrole-based polymers have been successfully used in biosensors to detect urea by means 
of ureasa entrapped in it [163], and in those where glucose oxidase is immobilised in a polypyrrole 
hybrid film, displaying very good performances [126,164,165]. Other conducting polymers have been 
used. For example, polyaniline was used to detect antibodies [166], and poly(allylamine) derivatives 
incorporating a charge transfer mediator have also proved to be efficient for enzyme-based 
amperometric biosensors [59,136,167]. In the last decades, natural polymers, such as chitosan 
derivatives, have been proposed to immobilize biologically-active species because of their 
advantageous features such as inertness, biocompatibility, good mechanical resistance, and appropriate 
film-forming properties [168]. For instance, a biosensor to determine the tumour marker, α-1-feto-
protein, whose biorecognition element is an enzyme-labelled antibody, takes advantage of this polymer 
and a reasonable stability has been reported [169]. A number of other biosensors for clinical 
applications using modified surfaces with chitosan polymer have been proposed, for example, to detect 
Schistosoma japonicum antigen [26], dengue virus oligonucleotide sequences [170], and to determine 
choline; in this latter case the enzyme cholinesterase was cross-linked with glutaraldehyde in a 
chitosan gel [171]. Reviews focusing on polymers used to assemble amperometric biosensors are 
referenced in [172-174]. 
3. Sensitivity 
One of the most relevant tasks when designing a ready-to-use biosensor is to achieve the needed 
sensitivity. In all cases, the aimed limit of detection, dynamic range, and sensitivity will depend on the 
natural sample where the device is to be used. Therefore, the expected range of analyte concentration 
and the interfering substances potentially present in the sample will largely influence the requirements. 
Enhancing any analytical method sensitivity means increasing the signal-to-noise ratio. Two 
obvious lines of attack are possible: augmenting the signal or diminishing the noise. In electron 
transfer-based biosensor technology, an enhancement of the signal-to-noise ratio is achieved by 
increasing the number of electroactive detectable analyte-related species and/or by lowering the 
interferences that reach the electrode thus giving rise to background current noise. The main strategies 
used to diminish the background currents produced by interferences have already been addressed in 
point 2.2. Hence, the “lowering the noise” subject will not be further detailed; we will therefore 
converge on the topic of signal boosting, which has been faced in the manners described below. 
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3.1. Magnifying the electron-transfer process 
Different ways of achieving the goal of increasing the number of detectable species are possible, 
two of which are based on magnifying the electron-transfer process, namely: 
(i) Recycling the electrochemically-transformed compound. This has already been described 
above in item 2.2 when considering catalytic enzymatic cycles involving the regeneration of 
the active-site of the redox enzyme using a charge transfer mediator that is then electro-
transformed at the electrode surface (see Fig. 7). Usually, in these cases, the enzyme substrate 
should be present at excess concentration to keep the enzymatic cycle. The signal that 
evidences the occurrence of the enzymatic cycle is generally related to the presence (or 
absence) of the analyte in the sample when performing an indirect (or competitive) 
immunoassay with electrochemical detection, as described previously in point 2.1.2. 
(ii) Amplifying the electron exchange process at the electrode surface using coupled enzymatic 
systems. In this approach, the analyte (or one analyte-related species), is the substrate of the 
first enzyme (Ez-1). The analyte and the Ez-1 co-substrate, which is the electro-active species, 
react with Ez1 to render the products, one of which is the Ez-2 substrate (Fig. 8). Ez-2 reacts 
with its substrate to regenerate the analyte (or the analyte-related species), thus enabling its 
recycling to keep consuming Ez-1 co-substrate, this latter one being electrochemically 
detected. Therefore, even tiny amounts of the analyte can be detected because the consumption 
of the electroactive species is supported by the cyclic reaction of both enzymes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Several examples taking advantage of such bi-enzymatic amplification have been described to 
detect chatecolamines [175,176], IgG and cocaine [176], among others. This approach was also used to 
detect successfully lactate via coupling the enzymes lactate oxidase and lactate dehydrogenase, 
immobilised onto aminopropyl controlled-pore glass [177], or a polyaniline film [178]. The basis of 
these clinically-relevant biosensors is that one of the products of the first enzymatic reaction is the 
substrate of the second enzyme, which transforms this product back to the initial species. This cyclical 
side product 
electroactive species 
and Ez-1 co-substrate 
analyte and  
Ez-1 substrate 
Ez-1 product and 
Ez-2 substrate 
Ez-1 
Ez-2 
+
+
electrode e-
Figure 8. Schematic representation of a bi-enzymatic amperometric biosensor. 
The analyte, (     ) is recycled as long the electroactive species (    ) is consumed. 
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conversion allows one electrochemically-active species, acting as co-substrate of the first enzyme, to 
keep on being consumed, thus multiplying the measured signal.  
(iii) Producing additional equivalents of electroactive species, generated by a second enzyme that 
uses a “side product” of the first enzymatic reaction, which had rendered the first equivalent of 
electroactive species. An amperometric biosensor using this model was presented by Conrath et 
al. to detect inorganic phosphate [179]. In the clinical practice, phosphate levels in both blood 
and urine are determined as indicative of osteopathies, and of parathyroid function [180]. In 
Conrath’s proposal, the first enzyme, maltose phosphorylase, catalyses the reaction between 
the analyte and maltose, to render β-D-glucose-1-phosphate and α-D-glucose (4). This latter 
species is further transformed by mutarotase into to β-D-glucose (5). β-D-glucose acts as 
substrate of glucose oxidase to render glucuronic acid and hydrogen peroxide (6), which is the 
electrochemically detected species. Another enzyme, acid phosphatase, hydrolyses the “side 
product”, glucose-1-phosphate, generating an extra β-D-glucose (7), which will be also further 
oxidised according to (6), thus releasing the analyte, phosphate, which can be recycled again. 
 
In this interesting example, the signal is not only amplified by the extra amount of substrate 
rendered by the acid phosphatase using a “side product”, but also by recycling the analyte [179]. 
3.2. Increasing the number of biorecognition species 
The obvious tactic to raise the amount of the electrochemically-detectable species is enlarging the 
number of biologically-active molecules in the biorecognition layer, so as to make the analyte-
capturing step more efficient. Self-assembled monolayers have proved to be useful in biosensor design 
but, many times, these structures do not offer the desired signal-to-noise ratio and, therefore, it has 
been proposed to use multilayer systems. Caruso et al. have demonstrated that the signal can be 
increased using devices with stratified-analogue structure where polymer layers are alternated with 
layers of the antibody, the analyte being the complementary antigen [181,182]. In a similar way, it has 
been shown signal enhancement when building up a layer-by-layer, organized supramolecular 
structure, comprised of a redox polymer and an enzyme-labelled antibody [137,167,183]. In both 
maltose + Pi α-D -glucose + β-D-glucose-1-P (4)
β-D-glucoseα-D-glucose (5)
β-D-glucose-1-P β-D-glucose + Pi (7)
glucuronic acid + H2O2β-D-glucose
electroactive species
(6)
acid
phosphatese
glucose 
oxidase
mutarotase
maltose
phosphorylase
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cases, the basic principle is that the electrochemical response obtained is proportional to the amount of 
the analyte-related species captured.  
Sometimes, a more precise control over surface density of biomolecules to prevent molecular 
aggregation, or to conduct their attachment in a favourable orientation, leads to improved biosensor 
performances. Calixarene derivatives have been proposed as linking structures to conduct effective 
protein immobilization [184]. In one proposal, the calixarene structure has thiol residues which link to 
the gold surface and, at the opposite side, a crownether structure remains exposed to further link the 
analyte-capturing biomolecule [185]. Thus, enhanced protein binding was achieved by modifying gold 
electrodes with calixarene-derived monolayers. 
Proper oriented attachment is crucial when the bioreactive species comprises a specific IgG 
antibody. IgG is a Y-shaped molecule, whose specific antigen-binding sites are located at the end of 
the “arms”, the so-called Fab region; the remaining extremity of the molecule, i.e. its base, is named Fc 
region. When self-assembling IgG-based immunoelectrodes, IgG molecules attach randomly to the 
surface, and only a fraction of them are useful to capture the analyte. In these cases, it is desired that 
the IgG Fab region is favourably oriented so as to prevent blockage of the binding sites to effectively 
capture the antigen. Early studies dealing with this issue were performed by Caruso et al. [186]. They 
demonstrated that electrodes whose surface had been modified with protein A, a molecule that displays 
high affinity for the Fc region of IgG, increased the further-immobilized IgG molecule, correctly 
oriented to react with its target analyte [186]. Using the oriented-linking principle to attach the 
bioreactive molecules, it has been possible to build an electron-transfer based biosensor to detect 
Staphilococcal enterotoxin B [187]. Moreover, recent studies on biosensors to determine thrombin 
have demonstrated the critical importance on the immobilization step. The work demonstrates that the 
efficiency to capture the analyte was enhanced when using streptavidin-biotine interactions to 
favourably orient the bioreceptor attachment [48]. In line with this, our group has reported preliminary 
results on one biosensor to detect specific chagasic antibodies whose capturing antigen is a genetically 
modified protein tailored to react oriented with a carbodiimide-activated surface. The device has 
shown sensitivity enhancement as compared with biosensors assembled with the same antigen 
recognition sites, but without the selective, oriented attachment onto the activated surface [31]. 
Additionally, we could enhance not only the sensitivity but also the selectivity of the method as 
mentioned above in item 2.1.2.  
Recently, nanotechnology has emerged as the “star” to achieve the signal-augmentation task. 
Indeed, the last decade has witnessed the blooming of biosensor technology involving nanomatter 
[188-191]. The problem is once more tackled by boosting the number of available active sites to 
interact with the analyte.  
Nanomatter is composed of unique functional materials that display incomparable characteristics 
related with their shape, structure and size (in the order of 1 to 100 nm scale) [192]. According to their 
shape, nanomaterials have been classified into nanowires, nanotubes, nanobelts, nanosprings, nanorods 
and nanoparticles. In connection with biosensors, among the most outstanding features of 
nanomaterials are their mechanical strength, their efficient and tuneable electron-transport properties, 
and their high surface area per volume unit [188]. Directly related with their arrangement, electron-
transfer process may be largely influenced by charge diminution or accumulation when taking place in 
a linear, one-dimension (1-D) structure, as for example, in a nanowire. This does not occur in a 2-D 
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structure, such as a virtually planar film. When charge transport occurs in a 2-D structure, electrons 
can be transferred along different conducting roads, even those that circumvent high or low charge 
density sites. On the other hand, charge transport in nanowires or nanotubes takes place along the line 
direction, which is the only path available to transfer electrons. This makes these materials competent 
to give a response upon perturbations from even a few molecules interacting along the line [188,193]. 
Together with this exceptional susceptibility, and in relation to their high surface-to-volume ratio, 
nanomaterials offer massive number of sites that can be chemically functionalized. When building 
electrochemical biosensors, this is translated into a plethora of analyte-interacting sites, thus leading to 
sensitivity enhancement [188-190]. 
Depending on the nanostructure composition, several strategies have been proposed to modify the 
nanomaterial surface, generally proceeding according to the methods already established to develop 
amperometric biosensors. For example, gold nanoparticles were utilized to develop amperometric 
biosensors to determine IgG [194], hepatitis B surface antigen [195], and lactate [196], among others. 
Also gold nanotubes have been modified by alkylthiols to which the enzymes of interest  had been 
attached, thus allowing to determine clinically-relevant analytes [197,198]. The enzymes glucose-
oxidase and horseradish-peroxidase, commonly used in clinical biosensor technology, have been 
covalently linked via activation using carbodiimide, or cross-linking it with glutaraldehide [197,198]. 
The same principle described above when addressing DNA-biosensor technology, in which metallic 
electrochemical mediators are used to catalyse G oxidation, has been also used together with 
functionalized carbon nanotubes (CNT) to detect the hybridisation event. In this case, the detection 
limit has been lowered to a few attomoles of the analyte [199]. In another example, the already known 
discriminative properties of Nafion were combined with the recently-demonstrated hydrogen peroxide 
catalytic properties of CNT [200]. Thus, Wang et al. have reported that it is feasible to suspend CNT 
in Nafion solutions, the resulting system showing a dramatic decrease of the overpotential for 
hydrogen peroxide detection; this provides an improved way towards glucose-oxidase biosensors 
development [200]. It was also demonstrated the feasibility of designing biosensors useful for clinical 
chemistry analysis by means of CNT-based pastes biocomposite bioelectrodes [201].  
The vast number of recently published work involving nanotechnology to design 
electrochemically-based biosensors demonstrates that this is one of the most fertile fields of research, 
and that prospects of biosensors useful for clinical diagnosis will be closely related to it. Thorough 
reviews on this subject are referenced as [188-190,193,202]. 
4. Simplicity of use and packaging 
Protocols to be followed when using biosensors should be as simple as possible, so that the device 
operation results amenable. This is an important feature to bear in mind, since it is usually related to 
market acceptability.  
Generally, the use of classical amperometric-based biosensors requires a number of consecutive 
steps. Clever solutions to shorten procedures have been reported, for example, by performing 
separation-free immunoassays [203]. These amperometric biosensors relay on a self-assembled 
antibody monolayer attached onto a double-sided microporus gold electrode. The layout allows spatial 
separation between the excess of conjugate in solution and the conjugate bound to the bioreceptor 
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layer. Therefore, the proposal has advantages with respect to common ELISA, such as fewer steps and 
the possibility of performing it in the field [204-206].  
Label-free biosensors have also become attractive because of their easiness of use. An outstanding 
approach has been proposed to determine glucose using glucose-oxidase directly “plugged” to the 
electrode taking advantage of the controlled electron transference through a CNT [207]. The electrode 
surface was thiolated, and CNTs were covalently aligned using carbodiimide. The enzyme co-factor 
was also covalently attached at the opposite end of the nanotubes by using carbodiimide. Finally, the 
apoenzyme was added, the enzyme was effectively reconstituted and glucose transformation into 
glucuronic acid was then monitored by amperometry, without using any charge transfer mediator 
[207]. The reader is referred to a recent review on contacting redox proteins using nanotechnology 
[208]. In another example, hCG was detected using an immunosensor where Abs against this 
pregnancy-indicator hormone had been oriented attached by means of protein A. hCG concentration 
was determined measuring the peak current by square wave stripping voltammetry [209]. Additional 
applications where label-free biosensors were used can be found in the following references [210-214]. 
Some of them also present renewable devices, another attractive characteristic aimed to lower the cost 
of the analysis [212].  
In addition, the need to move classical analytical tools into miniaturised devices is easily 
understood, since the latter ones reduce production and operative costs, apart from attenuating 
environmental impact. Certainly, the possibility of working in the micro-scale allows to use few 
microliters of reagents, thus making the operation not only cheaper than when using macro/semimicro 
scale techniques but also less hazardous [215]. The development of clinically-useful biosensors is 
moving in that direction due to the fact that the reactant requirements are definitely lower than those of 
classical methodologies. Micro-scale biosensor devices intrinsically have the ability to react with the 
analyte and generate a measurable response within the same compact body. A good example is the 
enzymatic biosensor to detect lactate in saliva in a one-step analysis [216]. The system consists of a 
silicon wafer where a three-electrode cell is built up. Lactate oxidase is entrapped in an agarose gel 
placed inside a cavity of the silicon chip. The sample diffuses through the pores, and the product of the 
enzymatic reaction is detected by amperometry [216].  
5. Future directions 
Even though it is desirable to perform the clinical-chemistry analysis in only one step, sometimes 
the complexity of the sample carrying the analyte and/or its low concentration make us to face with 
challenging problems. The progress in microfluidic systems allows for integration of different steps to 
perform the analysis within a single package [217-219]. The steps may include pretreatments, such as 
filtration, pre-concentration, extraction, derivatization, reaction and, eventually, analyte detection 
[220]. The so-called lab-on-a-chip technology has emerged as a gifted tool to cope with these real 
complex samples [217,221]. At the present time, schemes of biosensors coupled to layouts allowing 
for separative or pre-concentration steps are promising tools to deal with complex-matrix samples 
[217]. A novel approach has been reported to detect nucleic acids, which illustrates the matter [222]. 
The device consists of an ultramicroelectrode array where a glass chip is integrated with 
poly(dimethylsiloxane) channels. An electroactive compound is carried inside liposomes labeled with 
one ss-DNA tag. Another additional ss-DNA probe is linked to superparamagnetic beads, the target ss-
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DNA being complimentary to both tags. A magnet captures the liposome-analyte-magnetic bead 
sandwich inside the microfluidic channel, where the electroactive compound is released to be further 
electrochemically detected [222]. This appliance is a good example of compact ultra-micro systems 
that combine microfluidics and amperometric based biosensors.  
Considering that samples for clinical analysis are largely complex, the above-mentioned appliances 
are foreseen as the next-generation diagnostic devices [23]. Furthermore, these devices can help even 
when the problem magnifies because not only the sample but also the disease is complex, which is the 
case of cancer. This illness may be shuttled by a variety of genetic or/and epigentic changes directly 
acting on the overgrowth capacity of the cells. Up to these days, there is not a unique, specific tumor 
marker that could be used as indicator of every existing type of cancer. Numerous alterations on 
oncogenes or tumor-suppresor genes may be associated with cancer development, in such a way that 
using a single DNA-genosensor may not allow to diagnose the illness. Indeed, apart from DNA 
changes related to cancer, many other alterations occur during the disease. For example, multiple 
variations evidenced as over/under expression of certain proteins or mRNA, lead to an enormous 
number of different biomarkers that can be associated with the more than 200 types of cancer 
[223,224]. In such a complex scenario, new tools are necessary to perform simultaneous measurements 
of various analytes that generate multiple signals at the same time. Biosensors for clinical-chemistry 
analysis have demonstrated to move towards simplifying the analytical procedures with the advantage 
of multiplexing capability [23]. It is worth mentioning that this possibility can provide the physician 
important information that will facilitate early cancer detection. This is a critical point for treating the 
disease at an early stage, a fact that leads to improved prognosis [23,224]. Additionally, it is also 
important to monitor the anti-tumoral drug concentration in the patient’s fluids as a means to adjust the 
doses necessary to keep effectiveness of the treatment. In connection with this, it has been proposed a 
biosensor to detect one of the most used chemotherapy medication, cisplatin [225], using the same 
strategy already mentioned to determine heavy metal concentration in human fluids [116]. Petrlova’s 
et al. work [225], is another example in reference to biosensor technology as a powerful option to get 
clinically relevant information. 
Up to now, most of clinical analysis is carried out in centralised laboratories were high-technology 
equipment is available, and trained personnel perform the determinations under almost ideal 
conditions, i.e. temperature control, use of standard solutions and calibrators, etc. Nevertheless, the 
actual trend in clinical practice to monitor the health-state of the patient is directed towards point-of-
care screening analysis, and household equipment  [226-228]. Moreover, most underserved population 
in developing countries do not access to state-of-the-art diagnostic methods [229]. The emergence of 
technology that changes sophisticated diagnostic tools by low-cost, accurate and portable systems 
seems to be an urgent need, making possible to reach even rural people who hardly move to Health 
Centres [24]. Nowadays, the development of such new technology seems reachable. Research on 
biosensors, biotechnology, nanomaterials and microfluidics forefront technology, interacting 
synergistically, is expected to greatly help to achieve this goal. 
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